The fund manager AllianceBernstein looked at periods where the top 10 stocks dominated over the last three decades.

Applications for mortgages in the latest week rose in spite of the 30-year rate inching up for the fourth week in a row to ...

Hedge funds are picking up stocks in nuclear power producers in seeking to capitalize on the artificial intelligence boom, ...

A former Nomura employee has been charged with robbery, attempted murder, and arson of an inhabited building following an ...

The chances of another rate cut this year by the Bank of England has diminished after data showed an acceleration in the pace of Britain’s inflation last month.

The S&P 500 has bounced from its drop last week, a decline that had eroded its U.S. election bump without knocking the index off course toward a potentially big 2024 gain.

Delta Air Lines Inc. DAL on Wednesday reiterated its fourth-quarter financial outlook as the carrier laid out long-term goals as part of its investor day. Delta said two-thirds of millennials are ...

Tomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter @TomiKilgore. Back To Top ...

Sage Therapeutics Inc.’s stock SAGE fell 18% early Wednesday, after the company said a mid-stage trial of a treatment for cognitive impairment associated with Huntington’s Disease failed to meet its ...

Analysts tracked by FactSet expect Nvidia to post 75 cents in adjusted earnings per share for the fiscal third quarter, up from 40 cents a year before. The FactSet consensus calls for $33.2 billion in ...

Sage Therapeutics shares tumbled in premarket trading Wednesday after the biopharmaceutical company threw in the towel on dalzanemdor following the drug candidate's latest study failure. Sage shares, ...

Pfizer said the green light makes Hympavzi the first once-weekly subcutaneous treatment in the European Union for people with severe hemophilia B and the first to be administered via a pre-filled pen ...